

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 21493

Title: Effective treatment of gastrointestinal bleeding with Thalidomide - Chances and limitations.

Reviewer's code: 00035896

Reviewer's country: Canada

Science editor: Jing Yu

Date sent for review: 2015-07-17 19:08

Date reviewed: 2015-07-29 01:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Dr Bauditz nicely reviews the topic of the use of the drug Thalidomide for treatment of vascular malformations of the gut. The emphasis is on angiodysplasia and Osler Weber Rendu disease. Indications and mechanisms of action are outlined. I only have a few comments or suggestions before publication. The main minor issue is the handling of the other potential treatment for the same vascular malformations. On pg 7 end of first paragraph: the discussion of octreotide is in my opinion too dismissive. While true that there are no published randomized controlled trials there are at least 7 multi case series published. The largest by Nardone recently (98 cases Nardone G, et al, Dig Liver Dis. 2014). This paper and another by Junquera (Am J Gastroenterol, 2007) uses some historical controls or as with Nardone the same patients were compared after octreotide use. In addition there are now at least 2 meta-analyses of octreotide showing reasonable benefit (Jackson CS et al Am J Gastroenterol, 2014). I think the comment on octreotide could be expanded and then lead into the importance of thalidomide. The rest of the comments are about spelling or syntax Pg 5 3rd paragraph 4th line "teleangiectatic" should be "telangiectatic" Pg 7 1st paragraph 6th line



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

“ somatostatine” should be somatostatin Pg 8 1st paragraph top. The article by GE et al was published in 2011 not 2007. Please change Pg 8 2nd paragraph bottom; “clinical and experimental are very promising”. This is missing a word like “clinical and experimental findings are promising.